Business
Shareholdings update - REPLACEMENT
Shareholdings update - REPLACEMENT.
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\nThe following amendments have been made to the 'Shareholdings Update' announcement released on 31/03/2025 under RNS No 7637C.\nThe Company has approved the issue of the following ordinary shares and share options.\n545,455 new ordinary shares of 1p each (\"Additional Consideration Shares\") in the Company to 13 former shareholders (including employees) of Hutano Diagnostics Ltd, \n4,250,000 ordinary shares, in the form of unvested options, under the 2024-25 Company employee performance-related share option scheme,\nAll other details remain unchanged. The full amended text is shown below.\n \n------------------------------------------------------------------------------------------------------------------------\n \nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n\n \n03 April 2025\nEDX Medical Group plc\nAQSE: EDX\n(\"EDX Medical\" or the \"Company\")\n \nSHAREHOLDINGS UPDATE\n\nCAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces that the Company has approved the issue of the following ordinary shares and share options.\n\n545,455 new ordinary shares of 1p each (\"Additional Consideration Shares\") in the Company to 13 former shareholders (including employees) of Hutano Diagnostics Ltd, (\"Hutano\") a 100%-owned subsidiary of the Company since September 2023. The issue of these Additional Consideration Shares to the relevant Hutano shareholders is dependent on the achievement of certain commercial milestones, in this instance the successful passing of filing of a patent covering proprietary Point of Care testing technology.\n\n\n4,250,000 ordinary shares, in the form of unvested options, under the 2024-25 Company employee performance-related share option scheme, of which 3,750,000 are awarded to Mr Martin Walton, a director and deputy chair of the Company, under a performance schedule.\n\nOn March 20, EDX Medi...